A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadiotHErapy with or without ANdrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG PROMETHEAN)

Protocol No
NRG-GU011-PROMETHEAN
Principal Investigator
William Hall
Phase
II
Summary
This study is being done to answer the following question: Can we lower the chance of your prostate cancer growing or spreading by adding the drug relugolix to the usual radiation therapy? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your prostate cancer. The usual approach is defined as care most people get for prostate cancer.
Description
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer (NRG PROMETHEAN)
Participating Institutions
Drexel Town Center
Froedtert Menomonee Falls Hospital
Froedtert West Bend Hospital
Froedtert Hospital
Status
OPEN TO ACCRUAL